CommercialCoverageMedium impact
06.02.36d, Molecular Testing for the Management of Pancreatic Cysts or Barrett's Esophagus (Independence Administrators)
Independence Blue Cross·Gastroenterology, Oncology·Medical Policy
Effective date
Mar 5, 2025
We identified it
Jun 19, 2026
Summary
Independence Administrators issued a reissue of policy 06.02.36d regarding molecular testing for management of pancreatic cysts or Barrett's Esophagus, effective 03/05/2025. The billing team must review the full policy text to identify any changes to coverage criteria, prior authorization requirements, or billing code updates compared to the previous version.
Action Required
By 03/05/2025: Billing team must obtain and review the complete policy text from the provided URL to identify specific coverage changes, prior authorization requirements, and affected CPT/HCPCS codes for molecular testing related to pancreatic cysts or Barrett's Esophagus management. Update billing system, encounter forms, and provider documentation templates accordingly. Contact Independence Administrators if clarification is needed on specific billing codes or authorization procedures. Failure to implement required changes may result in claim denials or payment delays.